UNASSIGNED: Distant metastases arise in 20-30% of @entity1 with @entity957 of the @entity135 ( @entity213 ) in the 2 years following treatment. Therapeutic options are limited and the outcome of the @entity1 is poor. The identification of predictive biomarkers of @entity1 at risk for distant @entity3 and therapies are urgently needed. We previously identified a clinical subgroup, called @entity4960 " characterized by high propensity for rapid distant @entity3 . Here, we showed that @entity4960 " @entity1 do not or at very low level express @entity5689 ( @entity5689 ). Low or no expression of @entity5689 is of bad prognosis. Disappearance of @entity5689 enables cells to undergo epithelial-mesenchymal transition (EMT). EMT is associated with enhanced @entity4222 and invasion. Our study uncovered a new target, a5b1 integrin. Targeting a5b1 integrins might not only prevent @entity3 of @entity213 but also delay the development of the @entity5 by reducing @entity5 cell viability. @entity5689 detection might be taken into consideration in the future in the clinic not only to identify @entity1 at high risk of @entity3 but also to select @entity1 who might benefit from an anti-integrin therapy.

@entity5689 -negative @entity213 primary XXXX display increased epithelial to mesenchymal transition and prometastatic properties.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck'] @entity4222 :: ('MESH:D014085', 'Disease') :: ['migration'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity5689 :: ('857', 'Gene') :: ['Cav1', 'caveolin-1'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity4960 :: ('910', 'Gene') :: ['"R1'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC']
@entity5 :: (MESH:D009369,Disease) :: ['tumors']
